The Road to Success in ALS: Details of the AMX0035 CENTAUR Trial
December 18th 2019CENTAUR trial principal investigator Sabrina Paganoni, MD, PhD, discussed details of the phase 2 trial that helped investigators have the greatest chance of seeing a measurable treatment effect in patients with ALS.
James Wheless, MD: Perampanel Shows Sustained Real-World Efficacy
December 18th 2019The professor and chief of pediatric neurology, and director of the comprehensive epilepsy program and neuroscience institute at Le Bonheur Children’s Hospital, detailed his experience with patients treated with perampanel.
High-Dose Amantadine Improves Multiple Sclerosis-Related Walking Impairment
December 17th 2019Given the data, Adamas has stated that it will forgo its originally planned second phase 3 placebo-controlled study, instead continuing its open-label extension study and engaging the FDA to discuss ADS-5102’s regulatory pathway.
Sumeet Vadera, MD: Advances in Epilepsy Surgery
December 17th 2019The director of epilepsy surgery and associate professor of neurosurgery at UC Irvine spoke to the advances that have been made in epilepsy surgery and in noninvasive or minimally invasive techniques, as well as the impact they’ve had on outcomes.
Trial Will Assess Blood-Based Biomarker to Distinguish Epileptic From Psychogenic Seizures
December 15th 2019A new trial will aim to confirm the findings of a previous study that showed novel combinations of peripherally circulating proteins coupled with risk factors can provide a diagnostic tool with significant clinical unity.
FDA Approves ALS Drug Riluzole Oral Suspension for Use in Feeding Tubes
December 14th 2019A survey by the ALS Association found that 26% of patients reported having a PEG tube, which are typically inserted to allow for continued administration of nutrition, fluids, and medications as the disease progresses.
Galcanezumab Improves Episodic Migraine In Patients With Prior Failures
December 13th 2019Treatment with the calcitonin gene-related peptide (CGRP) inhibitor resulted in significant improvements in monthly migraine headache days across the groups assessed, including a significantly greater number of patients with ≥50% and ≥75% reductions.
FDA Approves Golodirsen for DMD Amenable to Exon 53 Skipping
December 13th 2019After receiving expedited review after receiving a Complete Response Letter in August, the therapy was approved based on data showing a statistically significant increase in dystrophin production in skeletal muscle.